Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
They have M Sheikh as a "executive"??
That guy helped the CYDY CEO (now indicted for fraud by SEC AND DOJ) with false narrative (LIES) and deserves to be indicted also
BIXT needs to correct the error or this can go down same path
IF this is a legit good drug--just need legit good trials for FDA approval
NOT paid PR pumper nonsense
Bioxytran $BIXT:
Yesterday announced a significant drop in viral load of influenza and RSV! The world is standing at the threshold of a new era in medical history and they’re selling it at .36!
I guess in 1928 with the advent of penicillin there were some that didn’t believe it!
I bought more at $.362!
And, can't sell this POS either!
Market yawned. No one believes the PRs they put out.
Terrible
Bioxytran $Bixt
Activity in Influenza and Respiratory Syncytial Virus highlights the broad- spectrum antiviral potential of novel drug ProLectin-M. See full news !
News on BIXT!
It’s good to see the ceo Dr David Platt get some recognition for his 30+ years of work! He was mentioned in the 22 page medical journal!
See news!
Which company? Bioxy or Todos?
Just processed 16k covid test over the weekend…companies one of the few making money…
I can vouch that the CEO of Todos needs help. Great product but the company continues to lose money..
Saw on another board that Tomdf might be that non toxic antiviral…maybe a partnership in the works?
Did Mike provide any new info on Thursday's program?
In the last interview he gave he mentioned the dosing study that is underway and mentioned that it would be followed by the Phase III trial "if funding is available". I sure hope the Phase III trial is performed.
That could easily happen after the 403 person clinical trial proves the drug works on everyone!
Green alert $Bixt talks in 4 mins Long Haul Covid19 antiviral
https://www.youtube.com/watch?v=EsHs0QLaWvc
When? All it takes is one whale, or leader of whales $$$$$$ to see what $BIXT has hiding out down here on OTC, specifically a whole new class on totally non toxic, antivirals that can be the next Moderna IMO.
I was one of the first to tell folks what a huge deal Moderna was in Feb 2020, and at the time it was still a no revenue, super cash eater experiment..... that became the holy grail of Covid19 rapid to market vaccines, FDA Warp Speed same humanity pandemic solver in a year, that use to take 10 years and 1/2 Billion dollars of major risk takers...to get to market.
Just need to right eyes on $BIXT.
It will happen. And maybe just as fast as Moderna, since the costs are lower and process is faster in India... and the market is massive in Asia...
The facility in India is FDA inspected, where the trial drug is made BTW...
In 1-2 years it is possible, they get bought out for Billions, or get a JV marketing / distribution deal with a Moderna or Pfizer or Novartis IMO....
In the interview, Mike Sheck indicated that they are starting their "dose optimization" study. After the study is completed they will then begin their phase III trials... of course he qualified this by adding "if funding is available".
When will this stock ever take off?
Watch this interview!
https://www.dropbox.com/s/l1d2v2nshekgdj1/bioxytran.mp4?dl=0
hey Mike,
Thanks for your dd and and all info on this company. I will invest not on your say so but because of all the associated info i have gleaned. but thanks !
This is amazing news!
Huge, major mega monster behemoth news out. $BIXT just approved for an IND Investigational New Drug Application trial for Long Haul Covid. Earlier $BIXT trials for covid19 outperformed Paxlovid, with 100% elimination of all measurable levels of Covid19 in the blood in as little as 3 days.
Almost no eyes on this story yet folks, 2022 high was $1.25
Lets go!!!!
https://www.otcmarkets.com/filing/html?id=16366618&guid=Jq2-kHEYY764dth
"ProLectin-I is an intravenous new chemical entity drug that is expected to treat Long COVID and Idiopathic Pulmonary Fibrosis (IPF). Long COVID is estimated to have 65 – 100 million cases worldwide. (1, 2) The CDC believes it affects one in five people that contract COVID-19. According to Harvard University, the economic cost of Long COVID is $3.7 trillion in the just the United States. IPF affects approximately 3 million people worldwide. (4) The disease primarily affects patients over the age of 50 and affects more men than women.
The top theory behind the pathogenesis of Long Covid is viral persistence (6) or viral fragments. ProLectin-I binds to the ‘galectin fold’ of the spike protein thereby neutralizing a replication competent viruses’ ability to infect other cells, but it also binds to spike protein fragments thought to be the cause of ongoing inflammation.
The medical term for scar tissue is fibrin. The word fibrosis stems from the continued growth of fibrin. Once scar tissue forms in the lungs combined with an already suppressed immune system, scar tissue can start to spread quickly.
The reason for scar tissue forming in the lungs can vary, but it can always be associated with the onset of lung damage.
Combining lung damage with an impaired immune system leads to scar tissue forming in the lungs. Multiple galectin types are associated with fibrosis, and ProLectin-I is thought to bind to a few."
8k https://www.otcmarkets.com/filing/html?id=16366618&guid=Jq2-kHEYY764dth
$BIXT 8k https://t.co/eDHaFuZSRs pic.twitter.com/rigs5voYwV
— i_like_bb_stock (@thommic) February 6, 2023
Emerging Growth Conference today was very informative. Company is making strides to approval !
Do we have news on the Phase III India trial yet? When is it expected to begin and do we have cash on hand to fund it?
I agree! It is very consistent indication of disease!
$BIXT Great discussions at #BiotechShowcase. One one one networking platform is amazing. Ppl need to take #galectins seriously. They are very powerful promoters of disease pathogenesis and need to be blocked. pic.twitter.com/QX5wM5J2GA
— Mike Sheikh (@MikeSheikh2) January 9, 2023
That is great, I would guess you mean trials not trails. No amount of "pumping" will help FDA approve. IF--this is legit--and the CEO is all you claim--go get funding from a foundation or join 1 of the govt research arms and let them add $$. Better yet partner with deep pockets big pharm.
But to use "questionable" persons with affiliation to charged CEOs that wrote pump articles for those CEOs--does not bode well as credible. Ask anyone @ CYDY about the "sheikh"
GLTU
$Bixt is a clinical stage company! Going to take more trails to get the large pipeline of drugs to market! Those trails are going to take money to do so. No one wants to see dilution of the stock ! Higher stock price equals less number of shares !
Look at the website. Crystal Research report
Avise Analytics report !
Mike presentations on Energing Growth conference
The existing trial data was better than Paxlovid from what I have seen so far. Still a long ways to go for this company, but I have read through the science and research and bio-chemistry and IMO this new technology could in several years make this company the new Moderna, not with a so called vaccine that is nothing more than what many call a dangerous experimental immune booster (There are pros and cons to the mRNA so called vaccines) but $BIXT has a new class of safe carbohydrate galectin chemistry that is non toxic, and oral or IV....capable, that has so far shocked us all at how well and fast it eliminated covid19 in early tests.
Time will tell, but for me, this is a technology that is worth supporting.. One of the few I have seen in decades in the biotech world... worth supporting.
I might add that Sars-Cov2 has proved for 3 years it is here to stay, based on current technology we have approved to fight it. The virus is adapting faster that out responses.
And new, more contagious versions Sars have been making deadly comebacks for 2 decades now.
With a very high effectiveness in clinical trails. Even back in 2020 it was successful!
China steals technology. That is why companies with any sense are leaving.
BIXT is on a fast track in India, so I have no clue what nonsense you are talking about regarding India taking it slow with the $BIXT Galectin antivirals technology.
I sent you a message on Twitter : Mike is a excellent writer with knowledge of science and drugs. He has been contacted to produce articles for a number of biotechs.
I have looked into BIXT the massive number of papers the CEO Dr Platt has written on Galectin and viruses!
Over 30 years of he career! BIXT is not the first company he has founded! Do your own DD ! BIXT is going to make medical history!
It could be the BIXT assoc w M Sheikh and his PR work. He did PR work (pump articles) for years for the former CEO of CYDY. That CEO has been arrested for pump/dump misleading (lies) shareholders. Looks very shady at best.
$BIXT Update on the failing badly competition
POLITICO: Once-favored Covid drugs ineffective on Omicron may be putting millions at risk.
https://www.politico.com/news/2023/01/01/omicron-covid-antibody-drugs-immunocompromised-00075285
Time to load the boat with $BIXT
Things are heating up fast in the US again
CNN: Omicron offshoot XBB.1.5 could drive new Covid-19 surge in US.
https://www.cnn.com/2023/01/03/health/covid-variant-xbb-explainer/index.html
This has Moderna Billion dollar + market cap start up written all over it. IMO, this tech will eclipse Moderna's
over the next 2-3 years...
Here is why:
https://microcapdaily.com/bioxytran-inc-otcmkts-bixt-crushes-primary-endpoint-expected-to-achieve-unicorn-status-in-new-year/
Happy New Year folks.
$BIXT has a one hell of a bright future, just like I said Moderna did in March 2020 before it's share price exploded
Happy to not take your advice and NOT selling.
BioXyTran Inc. is a biotech company that has recently announced positive results from a clinical trial of its COVID-19 antiviral drug, ProLectin-M. The trial showed that the drug was able to completely eliminate the virus in 100% of patients by day 7 and in 88% of patients by day 3. The drug works by blocking the viral docking of the virus to target cells, rather than by blocking viral replication from the inside, and is taken orally. BioXyTran has a strong background in carbohydrate chemistry and was able to pivot towards developing a carbohydrate-based antiviral for COVID-19 during the beginning of the pandemic. The company has faced adversity, including being suspended by the SEC and defaulting on debt, but has managed to regain trading status and secure backing from private equity and high-net-worth individuals. The potential success of ProLectin-M could have significant impact on the market for antivirals and on BioXyTran's valuation.
Houston we have $BIXT lift off. Telemetry confirms we are about to pass Mach 1...
$ land in sight
https://drive.google.com/file/d/1jzqUNg_4rXx2lySBPQF1C7G_u-8N4jbu/view?usp=share_link
Share this with everyone!
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |